The potential role of ER beta isoforms in the clinical management of breast cancer

C A Green; M B Peter; V Speirs; A M Shaaban

doi:10.1111/j.1365-2559.2008.02968.x

The potential role of ER beta isoforms in the clinical management of breast cancer

C A Green, M B Peter, V Speirs, A M Shaaban

University of Leeds

Research output: Contribution to journal › Review article › peer-review

20 Citations (Scopus)

Abstract

The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

Original language	English
Pages (from-to)	374-80
Number of pages	7
Journal	Histopathology
Volume	53
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2559.2008.02968.x
Publication status	Published - Oct 2008

Keywords

Animals
Antineoplastic Agents, Hormonal
Breast Neoplasms
Estrogen Receptor beta
Female
Humans
Models, Genetic
Protein Isoforms
Structure-Activity Relationship
Treatment Outcome
Journal Article
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2559.2008.02968.x

Cite this

@article{53e4e0ec6fb74429b829ed979f8689be,

title = "The potential role of ER beta isoforms in the clinical management of breast cancer",

abstract = "The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.",

keywords = "Animals, Antineoplastic Agents, Hormonal, Breast Neoplasms, Estrogen Receptor beta, Female, Humans, Models, Genetic, Protein Isoforms, Structure-Activity Relationship, Treatment Outcome, Journal Article, Review",

author = "Green, {C A} and Peter, {M B} and V Speirs and Shaaban, {A M}",

year = "2008",

month = oct,

doi = "10.1111/j.1365-2559.2008.02968.x",

language = "English",

volume = "53",

pages = "374--80",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Blackwell Publishing",

number = "4",

}

TY - JOUR

T1 - The potential role of ER beta isoforms in the clinical management of breast cancer

AU - Green, C A

AU - Peter, M B

AU - Speirs, V

AU - Shaaban, A M

PY - 2008/10

Y1 - 2008/10

N2 - The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

AB - The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

KW - Animals

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Estrogen Receptor beta

KW - Female

KW - Humans

KW - Models, Genetic

KW - Protein Isoforms

KW - Structure-Activity Relationship

KW - Treatment Outcome

KW - Journal Article

KW - Review

U2 - 10.1111/j.1365-2559.2008.02968.x

DO - 10.1111/j.1365-2559.2008.02968.x

M3 - Review article

C2 - 18312354

SN - 0309-0167

VL - 53

SP - 374

EP - 380

JO - Histopathology

JF - Histopathology

IS - 4

ER -

The potential role of ER beta isoforms in the clinical management of breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this